List view / Grid view
European Pharmaceutical Review spoke with Dean Petkanas from Neuropathix, formerly known as Kannalife, to find out why a CBD-inspired molecule can offer an improved therapeutic value.
Aubrey Dan explains how EmpowerPharm developed its synthetic CBD tablet and why a novel formulation could help combat a range of indications.
Michael Sassano from Somai Pharmaceuticals and Solaris Farms discusses the US and European markets for growing and extracting cannabinoids for the pharmaceutical industry.
European Pharmaceutical Review spoke with Dr Andy Yates to discuss Artelo Bioscience’s new CBD and TMP cocrystal, with the potential to treat PTSD.
Epidyolex, a cannabidiol oral solution, has been given approval by the FDA to treat seizures associated with tuberous sclerosis complex (TSC).
A new study has shown that in children and adolescents with an intellectual disability, cannabidiol (CBD) reduced severe behavioural problems.
A study conducted in the US has revealed that the majority of medical marijuana dispensed in the US has THC levels of up to 15 percent.
Researchers have modified a portable Raman spectrometer that can determine the level of THC in cannabis plants, which they say could be used by farmers wishing to grow hemp.
The UK government has changed the restrictions on importing cannabis-based medicine products into the country, allowing wholesalers to bring in larger quantities.
The ever-increasing demand for cannabis-based products requires US state regulators to set guidelines that ensure products are safe for human use. However, as medicinal cannabis moves forward at a rapidly increasing pace, regulations are falling behind. Here, Robert Thomas discusses the many inconsistencies across US states for monitoring levels of…
Within this in-depth focus are articles on how the regulation of heavy metals in cannabis can benefit from lessons learned in pharma and the advantages of using electron paramagnetic resonance (EPR) as an imaging technique.
Professor Trevor Jones, CBE, FMedSci is the new chairman of EMCA, a body that seeks to advocate for evidence-based policy and improving supply and manufacture of quality medicinal cannabis.
Dr Mohamedali discusses Canada's stance on medical cannabis and breaks down some misconceptions surrounding cannabinoids, as well as exploring the future for the pharmaceutical ingredient.
Cannabinoids are of growing interest in the pharmaceutical industry. Mark Tucker explains how this class of compounds is viewed across the world and why regulations surrounding them hinder their progress, yet remain necessary.
Dr Platt describes how medical cannabis can be used to treat conditions such as pain, his area of expertise. He also explains how perception has influenced the acceptance of cannabinoids.
